PTC Therapeutics
PTCT
#2862
Rank
โ‚ฌ4.15 B
Marketcap
52,71ย โ‚ฌ
Share price
0.90%
Change (1 day)
98.40%
Change (1 year)

P/E ratio for PTC Therapeutics (PTCT)

P/E ratio as of March 2025 (TTM): -6.61

According to PTC Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.60578. At the end of 2022 the company had a P/E ratio of -4.90.

P/E ratio history for PTC Therapeutics from 2013 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-4.90-8.6%
2021-5.36-41.41%
2020-9.15-14.84%
2019-10.7-15.78%
2018-12.859.1%
2017-8.02206.51%
2016-2.62-59.14%
2015-6.40-60.3%
2014-16.1166.28%
2013-6.06

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
38.4-681.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-9.46 43.26%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.4212-93.62%๐Ÿ‡บ๐Ÿ‡ธ USA
-9.95 50.60%๐Ÿ‡บ๐Ÿ‡ธ USA
-6.17-6.62%๐Ÿ‡บ๐Ÿ‡ธ USA
30.0-553.86%๐Ÿ‡จ๐Ÿ‡ญ Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.